{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:30:51Z","timestamp":1788845451956,"version":"build-2803163510"},"reference-count":311,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104068","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:40:52Z","timestamp":1777272052000},"page":"104068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care"],"prefix":"10.1016","volume":"25","author":[{"given":"Giuseppe","family":"Privitera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Andrea","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Dragoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Claudio","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pradelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104068_bb0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrgastro.2017.110","article-title":"The IBD interactome: an integrated view of aetiology, pathogenesis and therapy","volume":"14","author":"De Souza","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7351","key":"10.1016\/j.autrev.2026.104068_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104068_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ecco-jcc\/jjac127","article-title":"Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic and immune-inflammatory influences on the circulating methylome","volume":"17","author":"Kalla","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0020","first-page":"1","article-title":"Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential","volume":"0","author":"Meddens","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104068_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054562","article-title":"Distinct profiles of effector cytokines mark the different phases of Crohn\u2019s disease","volume":"8","author":"Zorzi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104068_bb0035","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/emm.2017.20","article-title":"Roles of intestinal epithelial cells in the maintenance of gut homeostasis","volume":"49","author":"Okumura","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2021.07.014","article-title":"Innate immune sensing by epithelial barriers","volume":"73","author":"Constant","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0045","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrmicro2546","article-title":"Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis","volume":"9","author":"Bevins","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.autrev.2026.104068_bb0050","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41385-018-0039-y","article-title":"Goblet cells: multifaceted players in immunity at mucosal surfaces","volume":"11","author":"Knoop","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/mi.2014.58","article-title":"Microbial sensing by goblet cells controls immune surveillance of luminal antigens in the colon","volume":"8","author":"Knoop","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature10863","article-title":"Goblet cells deliver luminal antigen to CD103 + dendritic cells in the small intestine","volume":"483","author":"McDole","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104068_bb0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.mucimm.2023.05.001","article-title":"MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 t-cell responses","volume":"17","author":"Heuberger","year":"2024","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1152\/physiol.00020.2018","article-title":"Monogenic intestinal epithelium defects and the development of inflammatory bowel disease","volume":"33","author":"Leung","year":"2018","journal-title":"Physiology"},{"key":"10.1016\/j.autrev.2026.104068_bb0080","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/ijms24032696","article-title":"CD4 T-Cell subsets and the pathophysiology of inflammatory bowel disease","volume":"24","author":"Gomez-Bris","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104068_bb0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/08820139.2018.1486411","article-title":"Intensified th9 response is associated with the immunopathogenesis of active ulcerative colitis","volume":"47","author":"Shohan","year":"2018","journal-title":"Immunol Invest"},{"key":"10.1016\/j.autrev.2026.104068_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1055914","article-title":"The role of th17 cells in inflammatory bowel disease and the research progress","volume":"13","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0095","first-page":"1","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7583","key":"10.1016\/j.autrev.2026.104068_bb0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature16460","article-title":"Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration","volume":"528","author":"Lindemans","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104068_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.autrev.2026.104068_bb0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/mi.2015.83","article-title":"IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis","volume":"9","author":"Martin","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41575-020-00362-9","article-title":"Deciphering the role of CD8+ t cells in IBD: from single-cell analysis to biomarkers","volume":"17","author":"Ray","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00630","article-title":"Plasticity of human CD4 t cell subsets","volume":"5","author":"Geginat","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2017.12.004","article-title":"Th17 plasticity and its relevance to inflammatory bowel disease","volume":"87","author":"Ueno","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104068_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107184","article-title":"Metabolic regulation of the Th17\/Treg balance in inflammatory bowel disease","volume":"203","author":"Zhang","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2026.104068_bb0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion.\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104068_bb0140","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.977394","article-title":"T-cell exhaustion in immune-mediated inflammatory diseases: new implications for immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0150","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/ibd\/izaa089","article-title":"Inflammatory bowel disease through the lens of single-cell RNA-seq technologies","volume":"26","author":"Corridoni","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0155","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2019-318343","article-title":"A blood-based prognostic biomarker in IBD","volume":"68","author":"Biasci","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0160","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41591-020-1003-4","article-title":"Single-cell atlas of colonic CD8+ t cells in ulcerative colitis","volume":"26","author":"Corridoni","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0165","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.3390\/cells11223554","article-title":"Advances in T cells based on inflammation in metabolic diseases","volume":"11","author":"Yu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104068_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of t-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0175","first-page":"1","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae066","article-title":"Exhausted lag-3+ CD4+ t cells are increased in pediatric inflammatory bowel disease","volume":"219","author":"Schnell","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104068_bb0185","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCRESAHA.116.309194","article-title":"Abandoning M1\/M2 for a network model of macrophage function","volume":"119","author":"Nahrendorf","year":"2016","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.autrev.2026.104068_bb0190","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41575-023-00769-0","article-title":"Macrophages in intestinal homeostasis and inflammatory bowel disease","volume":"20","author":"Hegarty","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0200","first-page":"814","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohns disease","author":"Schmitt","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.14740\/gr740w","article-title":"IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease","volume":"10","author":"Zhu","year":"2017","journal-title":"Gastroenterology Res"},{"key":"10.1016\/j.autrev.2026.104068_bb0210","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0215","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104068_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111192","article-title":"Temporal control of PDGFR\u03b1 regulates the fibroblast-to-myofibroblast transition in wound healing","volume":"40","author":"Yao","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104068_bb0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcmgh.2024.01.007","article-title":"Stromal cell regulation of intestinal inflammatory fibrosis","volume":"17","author":"Yang","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/reg2.77","article-title":"Macrophages and fibroblasts during inflammation and tissue repair in models of organ regeneration","volume":"4","author":"Mescher","year":"2017","journal-title":"Regeneration"},{"key":"10.1016\/j.autrev.2026.104068_bb0235","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104068_bb0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000528312","article-title":"Molecular basis of intestinal fibrosis in inflammatory bowel disease","volume":"7","author":"Andoh","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0245","series-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","first-page":"241","author":"Peyrin-biroulet","year":"2012"},{"key":"10.1016\/j.autrev.2026.104068_bb0250","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in crohns disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0255","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0260","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0265","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal crohns disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.autrev.2026.104068_bb0270","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network Meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0275","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe crohns disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0280","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0285","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0290","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for crohns disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0295","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0300","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0305","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0310","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active crohns disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0315","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/MEG.0000000000002411","article-title":"Adalimumab versus ustekinumab as first-line biological in moderate-to-severe crohns disease: real-life cohort from a tertiary referral center","volume":"34","author":"Moens","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0320","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izac167","article-title":"Comparative effectiveness of ustekinumab and anti-TNF agent as first-line biological therapy in luminal crohns disease: a retrospective study from 2 referral centers","volume":"29","author":"Rivi\u00e8re","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0325","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0330","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ueg2.12563","article-title":"Therapeutic sequencing in inflammatory bowel disease: determining the optimal position of vedolizumab for long-term crohns disease control using real-world evidence","volume":"12","author":"Louis","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"7","key":"10.1016\/j.autrev.2026.104068_bb0335","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.dld.2025.04.021","article-title":"Vedolizumab in inflammatory bowel disease: real-world outcomes and their prediction with machine learning\u2014the IG-IBD LIVE study","volume":"57","author":"Pugliese","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0340","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0345","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0350","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2024.2389985","article-title":"How comparative studies can inform treatment decisions for crohns disease","volume":"24","author":"Privitera","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0355","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","article-title":"Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn\u2019s disease patients failure to TNF-alpha inhibitors","volume":"117","author":"Onali","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104068_bb0360","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.14309\/ajg.0000000000003406","article-title":"IL-23p19 antagonists vs. ustekinumab for treatment of crohns disease: a meta-analysis of randomized controlled trials","volume":"120","author":"Dziegielewski","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe crohns disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0370","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active crohns disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0375","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0380","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae063","article-title":"Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"18","author":"Fumery","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0385","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0390","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0395","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.dld.2025.04.025","article-title":"Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: a multicenter cohort IGIBD study (VE2TO-UC)","volume":"57","author":"Noviello","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0400","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","volume":"12","author":"Allocca","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb0405","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gut.2005.084061","article-title":"Phenotype at diagnosis predicts recurrence rates in crohns disease","volume":"55","author":"Wolters","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0410","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0415","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide crohns disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","article-title":"Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease","volume":"104","author":"Romberg-Camps","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0425","first-page":"7","article-title":"Ulcerative colitis and colorectal cancer","volume":"4","author":"Gascogne","year":"1991","journal-title":"Cancer J"},{"key":"10.1016\/j.autrev.2026.104068_bb0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0435","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.3748\/wjg.v27.i47.8047","article-title":"Orphan patients with inflammatory bowel disease - when we treat beyond evidence","volume":"27","author":"Privitera","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cgh.2023.06.023","article-title":"Outcome of biological therapies and small molecules in ulcerative proctitis: a belgian multicenter cohort study","volume":"22","author":"Lemmens","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0445","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0450","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14712598.2024.2369189","article-title":"Management of proctitis in ulcerative colitis and the place of biological therapies","volume":"24","author":"De Deo","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0455","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with crohns disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0460","doi-asserted-by":"crossref","first-page":"i562","DOI":"10.1093\/ecco-jcc\/jjac190.0565","article-title":"P435 real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing crohns disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study","volume":"17","author":"Buisson","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0465","article-title":"Tu1787 VEDOLIZUMAB as a medical therapy for symptomatic stricturing small bowel Crohn\u2019s disease - results from an international multicenter cohort study","volume":"164","author":"El Ouali","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0470","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/ibd\/izaa092","article-title":"Double biologic therapy for refractory stricturing crohns disease: a successful case of deep remission with ustekinumab and vedolizumab","volume":"26","author":"Elmoursi","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0475","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2014.183","article-title":"Long-term outcome of enterocutaneous fistula in patients with crohns disease treated with anti-TNF therapy: a cohort study from the GETAID","volume":"109","author":"Amiot","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0480","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/MCG.0000000000000607","article-title":"A systematic review assessing medical treatment for rectovaginal and enterovesical fistulae in crohns disease","volume":"50","author":"Kaimakliotis","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0485","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ecco-jcc\/jjw016","article-title":"Outcomes of medical and surgical therapy for entero-urinary fistulas in crohns disease","volume":"10","author":"Taxonera","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0490","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/j.cgh.2023.01.013","article-title":"Adalimumab in biologic-na\u00efve patients with crohns disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID","volume":"21","author":"Bouhnik","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0495","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cgh.2019.05.027","article-title":"Efficacy and safety of tumor necrosis factor antagonists in treatment of internal fistulizing crohns disease","volume":"18","author":"Bouguen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0500","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in crohns disease but not in ulcerative colitis: systematic review and Meta-analysis","volume":"30","author":"Law","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0505","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0510","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2468-1253(25)00233-X","article-title":"Vedolizumab in early and late crohns disease (LOVE-CD): a phase 4 open-label cohort study","volume":"11","author":"D\u2019Haens","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0515","article-title":"Epidemiology and natural history of perianal Crohn\u2019s disease: a systematic review and meta-analysis of population-based cohorts","volume":"28","author":"Tsai","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0520","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","article-title":"AGA technical review on perianal Crohn\u2019s disease","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0525","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/j.cgh.2021.04.007","article-title":"Perianal crohns disease is associated with poor disease outcome: a nationwide study from the epiIIRN cohort","volume":"20","author":"Atia","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0530","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/apt.17836","article-title":"Burden of perianal disease in crohns disease: accelerating medical therapy and high rates of perianal surgery over the last four decades \u2013 results from a population-based study over four decades","volume":"59","author":"Gonczi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0535","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO guidelines on therapeutics in crohns disease: surgical treatment","volume":"18","author":"Adamina","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0540","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with crohns disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0545","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing crohns disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0550","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0555","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with crohns disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb0560","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ibd\/izac103","article-title":"Comparative efficacy of biologic therapies for inducing response and remission in fistulizing crohns disease: systematic review and network Meta-analysis of randomized controlled trials","volume":"29","author":"Shehab","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0565","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ecco-jcc\/jjad185","article-title":"Pharmacological therapies for the management of fistulizing crohns disease: a systematic review and Meta-analysis","volume":"18","author":"Vuyyuru","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0570","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MEG.0000000000001561","article-title":"Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in crohns disease","volume":"32","author":"Plevris","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0575","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with crohns disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0580","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.14309\/ajg.0000000000001111","article-title":"Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing crohns disease: an ACCENT-II post hoc analysis","volume":"116","author":"Papamichael","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0585","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","article-title":"Higher anti-tumor necrosis factor-\u03b1 levels correlate with improved radiologic outcomes in crohns perianal fistulas","volume":"20","author":"De Gregorio","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0590","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising crohns disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0595","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Fistula healing in pivotal studies of ustekinumab in crohns disease","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0600","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn\u2019s disease: a post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0605","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (cx601) for complex perianal fistulas in crohns disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0610","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","article-title":"OP18 efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and crohns disease: results from the global ADMIRE-CD II phase 3 study","volume":"18","author":"Serclova","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0615","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02484-6","article-title":"Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn\u2019s disease: a retrospective observational study","volume":"12","author":"Park","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0620","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1053\/j.gastro.2019.02.005","article-title":"Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with crohns disease","volume":"156","author":"Dige","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0625","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2017.04.001","article-title":"Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with crohns disease","volume":"153","author":"Dietz","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0630","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO guidelines on therapeutics in crohns disease: surgical treatment","volume":"14","author":"Adamina","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0193-x","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2026.104068_bb0640","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2036.2012.05002.x","article-title":"Review article: the natural history of postoperative crohns disease recurrence","volume":"35","author":"Buisson","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0645","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae070","article-title":"Re-resection rates and disease recurrence in Crohn\u2019s disease: a population-based study using individual-level patient data","volume":"18","author":"Poulsen","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0650","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/ecco-jcc\/jjad053","article-title":"Results of the eighth scientific workshop of ECCO: prevention and treatment of postoperative recurrence in patients with crohns disease undergoing an ileocolonic resection with ileocolonic anastomosis","volume":"17","author":"Ferrante","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0655","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of crohns disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0660","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2468-1253(20)30394-0","article-title":"Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the global interventional inflammatory bowel disease group","volume":"6","author":"Shen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0665","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","article-title":"Crohn\u2019s disease management after intestinal resection: a randomised trial","volume":"385","author":"De Cruz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0670","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ecco-jcc\/jjad055","article-title":"Results of the eighth scientific workshop of ECCO: diagnosing postoperative recurrence of crohns disease after an ileocolonic resection with ileocolonic anastomosis","volume":"17","author":"Dragoni","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0675","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/apt.14944","article-title":"Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in crohns disease: results from a prospective cohort study","volume":"48","author":"Auzolle","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0680","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3390\/biomedicines12112434","article-title":"Managing Crohn\u2019s disease postoperative recurrence beyond prophylaxis: a comprehensive review with meta-analysis","volume":"12","author":"Olteanu","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.104068_bb0685","article-title":"Post-operative prevention and monitoring of Crohn\u2019s disease recurrence","volume":"10","author":"Lee","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.autrev.2026.104068_bb0690","first-page":"104","article-title":"Anastomosis after bowel resection for crohns disease: state of the art review","volume":"38","author":"Newton","year":"2024","journal-title":"Clin Colon Rectal Surg"},{"key":"10.1016\/j.autrev.2026.104068_bb0695","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-0040-1714236","article-title":"Surgical treatment for crohns disease: a role of Kono-S anastomosis in the west","volume":"33","author":"Kono","year":"2020","journal-title":"Clin Colon Rectal Surg"},{"key":"10.1016\/j.autrev.2026.104068_bb0700","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjad176","article-title":"Does Kono-S anastomosis reduce recurrence in crohns disease compared with conventional ileocolonic anastomosis? A nationwide propensity score-matched study from GETAID chirurgie group [KoCoRICCO study]","volume":"18","author":"Alibert","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0705","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjv076","article-title":"Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal crohns disease recurrence","volume":"9","author":"Ferrante","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0710","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ecco-jcc\/jjac139","article-title":"Benefit of risk-stratified prophylactictreatment on clinical outcome in postoperative Crohns disease","volume":"17","author":"Joustra","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0715","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjae011","article-title":"Prophylactic versus endoscopy-driven treatment of crohns postoperative recurrence: a retrospective, multicentric, European study [PORCSE study]","volume":"18","author":"Geldof","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0720","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cgh.2020.03.064","article-title":"Rates of postoperative recurrence of crohns disease and effects of immunosuppressive and biologic therapies","volume":"19","author":"Rivi\u00e8re","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0725","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ueg2.12367","article-title":"Comparison of two strategies for the management of postoperative recurrence in crohns disease patients with one clinical risk factor: a multicentre IG-IBD study","volume":"11","author":"Dragoni","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb0730","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/apt.18001","article-title":"Crohn\u2019s disease after surgery: changes in post-operative management strategies over time and their impact on long-term re-operation rate\u2014a retrospective multicentre real-world study","volume":"59","author":"Aratari","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0735","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of crohns disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0740","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents crohns disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0745","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/ibd.21928","article-title":"Scheduled infliximab monotherapy to prevent recurrence of crohns disease following ileocolic or ileal resection: a 3-year prospective randomized open trial","volume":"18","author":"Yoshida","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0750","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/ajg.2013.287","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of crohns disease: a randomized controlled trial","volume":"108","author":"Savarino","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0755","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13353","article-title":"Efficacy of thiopurines and adalimumab in preventing crohns disease recurrence in high-risk patients - a POCER study analysis","volume":"42","author":"De Cruz","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0760","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/ecco-jcc\/jjx051","article-title":"Adalimumab vs azathioprine in the prevention of postoperative Crohns disease recurrence. A GETECCU randomised trial","volume":"11","author":"Vera-Mendoza","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0765","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","article-title":"Risk prediction and comparative efficacy of anti-TNF vs thiopurines, for preventing postoperative recurrence in crohns disease: a pooled analysis of 6 trials","volume":"20","author":"Beelen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0770","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2468-1253(24)00317-0","article-title":"Vedolizumab to prevent postoperative recurrence of crohns disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"D\u2019Haens","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0775","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ueg2.12068","article-title":"Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in crohns disease","volume":"9","author":"Buisson","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb0780","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/ecco-jcc\/jjac100","article-title":"Endoscopic postoperative recurrence in crohns disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world multicentre european study","volume":"16","author":"Yanai","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0785","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dld.2022.07.013","article-title":"Ustekinumab and vedolizumab for the prevention of postoperative recurrence of crohns disease: results from the ENEIDA registry","volume":"55","author":"Ma\u00f1osa","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0795","first-page":"453","article-title":"Fried frailty phenotype assessment components as applied to geriatric inpatients","volume":"11","author":"Bieniek","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.autrev.2026.104068_bb0800","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jamda.2017.07.005","article-title":"FRAIL questionnaire screening tool and short-term outcomes in geriatric fracture patients","volume":"18","author":"Gleason","year":"2017","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.autrev.2026.104068_bb0805","doi-asserted-by":"crossref","first-page":"ii46","DOI":"10.1093\/ecco-jcc\/jjae067","article-title":"Considerations on multimorbidity and frailty in inflammatory bowel diseases","volume":"18","author":"Carbery","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0810","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MIB.0000000000001033","article-title":"Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases","volume":"23","author":"Ghosh","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0815","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061426","article-title":"Frailty in aging and the search for the optimal biomarker: a review","volume":"10","author":"Sep\u00falveda","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.autrev.2026.104068_bb0820","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/jcm12020533","article-title":"Frailty and inflammatory bowel disease: a scoping review of current evidence","volume":"12","author":"Fons","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0825","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/ibd\/izac242","article-title":"Frail phenotype in patients with inflammatory bowel disease","volume":"29","author":"Salvatori","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0830","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.cgh.2022.01.001","article-title":"Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0835","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.gastha.2024.07.003","article-title":"Frailty and inflammatory bowel disease: a nationwide assessment","volume":"3","author":"Kilani","year":"2024","journal-title":"Gastro Hep Advances"},{"key":"10.1016\/j.autrev.2026.104068_bb0840","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ecco-jcc\/jjad175","article-title":"Frailty screening is associated with hospitalization and decline in quality of life and functional status in older patients with inflammatory bowel disease","volume":"18","author":"VER","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0845","first-page":"1","article-title":"Assessing causality between inflammatory bowel diseases with frailty index and sarcopenia: a bidirectional mendelian randomization study","volume":"29","author":"Wang","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.autrev.2026.104068_bb0850","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.13033","article-title":"Sarcopenia and frailty in inflammatory bowel disease: emerging concepts and evidence","volume":"8","author":"Neelam","year":"2024","journal-title":"JGH Open"},{"key":"10.1016\/j.autrev.2026.104068_bb0855","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2468-1253(23)00011-0","article-title":"Inflammation and malnutrition in inflammatory bowel disease","volume":"8","author":"Massironi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0860","article-title":"Investigation and analysis of frailty and nutritional status in patients with inflammatory bowel disease","volume":"7","author":"Liu","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.autrev.2026.104068_bb0865","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0870","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: a call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0875","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2024.1334308","article-title":"Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients","volume":"15","author":"Bernabeu","year":"2024","journal-title":"Front Psychol"},{"key":"10.1016\/j.autrev.2026.104068_bb0880","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ibd\/izad120","article-title":"Safety and monitoring of inflammatory bowel disease advanced therapies","volume":"30","author":"Bhat","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0885","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.dld.2024.02.002","article-title":"Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study","volume":"56","author":"Anisdahl","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb0890","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032","article-title":"AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: commentary","volume":"22","author":"Axelrad","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0895","article-title":"Comparison of the safety and efficacy of ustekinumab and vedolizumab in patients with Crohns disease: a systematic review and meta-analysis of propensity score matched cohort studies","volume":"12","author":"Pasta","year":"2024","journal-title":"Diseases Basel"},{"key":"10.1016\/j.autrev.2026.104068_bb0900","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and Meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104068_bb0905","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.3390\/jcm12072658","article-title":"Reversibility of frail phenotype in patients with inflammatory bowel diseases","volume":"12","author":"Salvatori","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2026.104068_bb0910","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10620-021-06990-8","article-title":"Inflammatory bowel disease patients who respond to treatment with anti-tumor necrosis factor agents demonstrate improvement in pre-treatment frailty","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2026.104068_bb0915","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad004","article-title":"Comparative effectiveness of non-pharmacological interventions for frailty: a systematic review and network meta-analysis","volume":"52","author":"Sun","year":"2023","journal-title":"Age Ageing"},{"key":"10.1016\/j.autrev.2026.104068_bb0920","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.gie.2011.06.023","article-title":"Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis","volume":"74","author":"Day","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.autrev.2026.104068_bb0925","doi-asserted-by":"crossref","first-page":"e1353","DOI":"10.1016\/j.cgh.2021.08.019","article-title":"Yield and predictors of surveillance colonoscopies in older adults with long-standing ulcerative colitis","volume":"20","author":"Sasson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0930","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb0935","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104068_bb0940","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0945","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb0950","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb0955","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104068_bb0960","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0965","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in inflammatory bowel disease: frequency, incidence and risk factors - results from the swiss IBD cohort study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0970","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of crohns disease: a Meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb0975","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb0980","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin\u2019s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0985","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with crohns disease with up to 6 years of follow-up in the pyramid registry","volume":"113","author":"D\u2019Haens","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb0990","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104068_bb0995","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1000","first-page":"680","article-title":"The risk of venous thromboembolic events in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Arvanitakis","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1015","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2023.02.042","article-title":"Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: a systematic review with meta-analysis","volume":"378","author":"D\u2019Ascenzo","year":"2023","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104068_bb1025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/medicina61010054","article-title":"Serum lipids alterations in patients under systemic JAK inhibitors treatments in dermatology: clinical aspects and management","volume":"61","author":"Paolino","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.autrev.2026.104068_bb1030","first-page":"1","article-title":"New restrictions on JAK inhibitors in the EU","volume":"8","author":"The Lancet Gastroenterology & Hepatology","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cgh.2022.06.011","article-title":"Risk of recurrent acute arterial events associated with thiopurines and anti-tumor necrosis factor in inflammatory bowel diseases","volume":"21","author":"Dheyriat","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1040","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb1045","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2026.104068_bb1050","series-title":"StatPearls Publishing","article-title":"Tumor necrosis factor inhibitors","author":"Gerriets","year":"2023"},{"key":"10.1016\/j.autrev.2026.104068_bb1055","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1060","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081839","article-title":"Extraintestinal manifestations in inflammatory bowel disease: from pathophysiology to treatment","volume":"12","author":"Faggiani","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.104068_bb1065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1075","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jgh.16612","article-title":"The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Zheng","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1080","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/cimb44050127","article-title":"The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases","volume":"44","author":"\u021aiburc\u0103","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.autrev.2026.104068_bb1085","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1090","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mayocp.2021.08.007","article-title":"A road map of the axial spondyloarthritis continuum","volume":"97","author":"Schwartzman","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2026.104068_bb1100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","article-title":"The term \u201cnon-radiographic axial spondyloarthritis\u201d is much more important to classify than to diagnose patients with axial spondyloarthritis","volume":"75","author":"Deodhar","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1110","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.160952","article-title":"Antitumor necrosis factor-\u03b1 therapy associated with inflammatory bowel disease: three cases and a systematic literature review","volume":"44","author":"Bieber","year":"2017","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104068_bb1115","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","article-title":"Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"19","author":"Bautista-Molano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1120","series-title":"Study Details | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis","year":"2026"},{"key":"10.1016\/j.autrev.2026.104068_bb1130","series-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","first-page":"258","volume":"71","author":"Deodhar","year":"2019"},{"key":"10.1016\/j.autrev.2026.104068_bb1125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104068_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103533","article-title":"The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian group for the study of inflammatory bowel disease (IG-IBD) and italian society of rheumatology (SIR) recommendations based on a pseudo-Delphi consensus","volume":"23","author":"Macaluso","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104068_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103638","article-title":"Treatment strategies for spondyloarthritis: implementation of precision medicine \u2013 or \u201cone size fits all\u201d concept?","volume":"23","author":"Proft","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104068_bb1150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/north american dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1165","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1170","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1175","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094681","article-title":"Inhibition of the JAK-STAT pathway in the treatment of psoriasis: a review of the literature","volume":"25","author":"Furtunescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104068_bb1185","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1190","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1195","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for Moderate-to-Severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb1200","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dot.2021.57.9.3293619","article-title":"An update on adalimumab for pyoderma gangrenosum","volume":"57","author":"Yamamoto","year":"2021","journal-title":"Drugs of Today"},{"key":"10.1016\/j.autrev.2026.104068_bb1205","series-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","first-page":"505","volume":"55","author":"Brooklyn","year":"2006"},{"key":"10.1016\/j.autrev.2026.104068_bb1210","doi-asserted-by":"crossref","unstructured":"Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. C Mugheddu, L Atzori, M Del Piano, A Lappi, M Pau, S Murgia, I Zucca, F Rongioletti Dermatologic therapy, Wiley Online Library 2017;30.","DOI":"10.1111\/dth.12527"},{"issue":"1","key":"10.1016\/j.autrev.2026.104068_bb1215","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14810","article-title":"Tofacitinib in pyoderma gangrenosum \u2013 a case series","volume":"27","author":"Sathyanarayana","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcjo.2024.07.013","article-title":"Anterior uveitis for the comprehensive ophthalmologist","volume":"60","author":"Xie","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104068_bb1225","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1230","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb1235","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb1240","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2026.104068_bb1245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000502816","article-title":"Therapies in inflammatory bowel disease patients with extraintestinal manifestations","volume":"101","author":"Juillerat","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.autrev.2026.104068_bb1250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.autrev.2026.104068_bb1255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104068_bb1260","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1265","first-page":"1111","article-title":"Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Alivernini","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.autrev.2026.104068_bb1270","doi-asserted-by":"crossref","first-page":"e1483","DOI":"10.1016\/j.cgh.2021.08.041","article-title":"Drug-related pneumonitis in patients receiving vedolizumab therapy for inflammatory bowel disease","volume":"20","author":"Pugliese","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1275","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000667","article-title":"Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis","volume":"4","author":"Alivernini","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104068_bb1280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1285","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/ueg2.70058","article-title":"Primary sclerosing cholangitis worsens prognosis in patients with inflammatory bowel disease: a propensity-matched cohort study","volume":"13","author":"D\u2019Amico","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb1290","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb1295","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/hepr.14029","article-title":"Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only","volume":"54","author":"Das","year":"2024","journal-title":"Hepatol Res"},{"issue":"13","key":"10.1016\/j.autrev.2026.104068_bb1300","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jama.1990.03440130133041","article-title":"Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options","volume":"263","author":"Eddy","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104068_bb1305","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making \u2014 the pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104068_bb1310","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31083\/j.rcm2408232","article-title":"Shared decision-making: the more the patient knows, the better the decision that is made","volume":"24","author":"Klein","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.autrev.2026.104068_bb1315","article-title":"The mediating role of shared decision-making in the effect of the patient\u2013physician relationship on compliance with treatment","volume":"8","author":"Deniz","year":"2021","journal-title":"J Patient Exp"},{"key":"10.1016\/j.autrev.2026.104068_bb1320","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Schoefs","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1325","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40271-015-0126-z","article-title":"Novel statistical approach to determine inflammatory bowel disease: patients perspectives on shared decision making","volume":"9","author":"Siegel","year":"2016","journal-title":"Patient"},{"key":"10.1016\/j.autrev.2026.104068_bb1330","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MIB.0000000000000740","article-title":"Patients with ulcerative colitis are more concerned about complications of their disease than side effects of medications","volume":"22","author":"Thompson","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/apt.17286","article-title":"Crohns disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial","volume":"57","author":"Zisman-Ilani","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1340","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/ibd\/izac104","article-title":"Risk factors for voluntary childlessness in men and women with inflammatory bowel disease","volume":"28","author":"Winter","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1345","article-title":"Inflammatory bowel disease and infertility: analysis of literature and future perspectives","volume":"92","author":"Carini","year":"2021","journal-title":"Acta Biomed"},{"key":"10.1016\/j.autrev.2026.104068_bb1350","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(24)00052-7","article-title":"Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation","volume":"403","author":"Nielsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb1355","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","article-title":"The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and Meta-analysis","volume":"15","author":"Kim","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/apt.17348","article-title":"Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a danish cohort study","volume":"57","author":"Vestergaard","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1365","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.dld.2023.08.054","article-title":"New drugs for the treatment of IBD during conception, pregnancy, and lactation","volume":"56","author":"Pugliese","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1370","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00384-011-1274-9","article-title":"Impact of ileal pouch-anal anastomosis on female fertility: Meta-analysis and systematic review","volume":"26","author":"Rajaratnam","year":"2011","journal-title":"Int J Color Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1375","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/ecco-jcc\/jjad079","article-title":"Female and male fertility after colectomy and reconstructive surgery in inflammatory bowel diesase: a national cohort study from Sweden","volume":"17","author":"Druvefors","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1380","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ecco-jcc\/jjab187","article-title":"Postpartum surgical complications in women with inflammatory bowel disease after caesarian section: a danish nationwide cohort study","volume":"16","author":"Friedman","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1385","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/apt.15587","article-title":"Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease","volume":"51","author":"Tandon","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1390","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1111\/1471-0528.13946","article-title":"Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes","volume":"123","author":"Shand","year":"2016","journal-title":"BJOG"},{"key":"10.1016\/j.autrev.2026.104068_bb1395","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/MIB.0000000000001113","article-title":"Indications for mode of delivery in pregnant women with inflammatory bowel disease","volume":"23","author":"Burke","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104068_bb1400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1405","first-page":"768","article-title":"Sexual and reproductive issues for men with inflammatory bowel disease","volume":"104","author":"Feagins","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb1410","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4292\/wjgpt.v7.i3.361","article-title":"Infertility in men with inflammatory bowel disease","volume":"7","author":"Shin","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1415","doi-asserted-by":"crossref","first-page":"ii16","DOI":"10.1093\/ecco-jcc\/jjae048","article-title":"Navigating reproductive care in patients with inflammatory bowel disease: a comprehensive review","volume":"18","author":"Sousa","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1420","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2174\/1871530319666190313112110","article-title":"Inflammatory bowel disease therapies adversely affect fertility in men- a systematic review and meta-analysis","volume":"19","author":"Banerjee","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.autrev.2026.104068_bb1425","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The cost of inflammatory bowel disease care: how to make it sustainable","volume":"23","author":"Burisch","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1430","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb1435","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14712598.2020.1839045","article-title":"Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients","volume":"21","author":"Pugliese","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1440","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.dld.2025.01.206","article-title":"Nonmedical switch of anti-TNF-\u03b1 biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER study","volume":"57","author":"Privitera","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1445","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ueg2.12357","article-title":"Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort","volume":"11","author":"Gros","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb1460","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/0929867324666170406112304","article-title":"Biosimilars for the management of inflammatory bowel diseases: economic considerations","volume":"26","author":"Gulacsi","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.autrev.2026.104068_bb1465","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","article-title":"Driving down the cost of biologics: lessons from a nationalised health-care system","volume":"404","author":"Russell","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104068_bb1470","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.18399","article-title":"Review article: Green management of IBD\u2014new paradigms for an eco-friendly approach","volume":"61","author":"Cammarota","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1475","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.NAJ.0000660032.02514.ec","article-title":"Reducing waste and increasing sustainability in health care settings","volume":"120","author":"Kleber","year":"2020","journal-title":"Am J Nurs"},{"key":"10.1016\/j.autrev.2026.104068_bb1480","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Chetwood","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1490","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1039\/b927443j","article-title":"Environmental considerations in biologics manufacturing","volume":"12","author":"Ho","year":"2010","journal-title":"Green Chem"},{"key":"10.1016\/j.autrev.2026.104068_bb1495","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820927550","article-title":"Complementary and alternative medications in the management of inflammatory bowel disease","volume":"13","author":"Picardo","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104068_bb1500","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cgh.2023.05.023","article-title":"Curcumin-QingDai combination for patients with active ulcerative colitis: a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Ben-Horin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1505","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.cgh.2020.01.046","article-title":"Dietary guidance from the international organization for the study of inflammatory bowel diseases","volume":"18","author":"Levine","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104068_bb1510","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in crohns disease patients with loss of response","volume":"18","author":"Katz","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1515","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11144037","article-title":"Similar levels of efficacy of two different maintenance doses of adalimumab on clinical severity and quality of life of patients with hidradenitis suppurativa","volume":"11","author":"Fania","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2026.104068_bb1520","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1007\/s10620-020-06567-x","article-title":"No difference of adalimumab pharmacokinetics when dosed at 40 mg every week or 80 mg every other week in IBD patients in clinical remission after adalimumab dose intensification","volume":"66","author":"Paul","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2026.104068_bb1525","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2026.104068_bb1530","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/MIB.0000000000001182","article-title":"Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice","volume":"23","author":"Aguas Peris","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2026.104068_bb1535","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/apt.14466","article-title":"Comparison of infliximab with adalimumab in 827 biologic-na\u00efve patients with crohns disease: a population-based Danish cohort study","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104068_bb1540","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for crohns disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2026.104068_bb1545","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.autrev.2026.104068_bb1550","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102832","article-title":"Combination therapy in inflammatory bowel disease \u2013 from traditional immunosuppressors towards the new paradigm of dual targeted therapy","volume":"20","author":"Privitera","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104068_bb1555","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a european retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2026.104068_bb1560","series-title":"Study Details | USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)","year":"2026"},{"key":"10.1016\/j.autrev.2026.104068_bb1565","series-title":"Study Details | A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease","year":"2026"},{"key":"10.1016\/j.autrev.2026.104068_bb1570","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.dld.2021.05.015","article-title":"Vaccinations in patients with inflammatory bowel disease","volume":"53","author":"Macaluso","year":"2021","journal-title":"Dig Liver Dis"}],"updated-by":[{"DOI":"10.1016\/j.autrev.2026.104109","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:37:47Z","timestamp":1780864667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":311,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1568997226000820"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104068","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104068"}}